Hall Laurie J Trustee increased its holdings in shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) by 2,430.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,290 shares of the biotechnology company’s stock after purchasing an additional 3,160 shares during the quarter. Hall Laurie J Trustee’s holdings in Sarepta Therapeutics were worth $224,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also made changes to their positions in the company. Jennison Associates LLC lifted its holdings in Sarepta Therapeutics by 103.9% in the third quarter. Jennison Associates LLC now owns 1,143,853 shares of the biotechnology company’s stock valued at $51,885,000 after acquiring an additional 582,894 shares during the period. Alyeska Investment Group L.P. purchased a new stake in Sarepta Therapeutics in the third quarter worth about $26,011,000. Voya Investment Management LLC increased its position in Sarepta Therapeutics by 2,786.1% in the second quarter. Voya Investment Management LLC now owns 568,525 shares of the biotechnology company’s stock worth $19,165,000 after buying an additional 548,826 shares in the last quarter. Gilder Gagnon Howe & Co. LLC increased its position in Sarepta Therapeutics by 3,599.4% in the third quarter. Gilder Gagnon Howe & Co. LLC now owns 534,087 shares of the biotechnology company’s stock worth $24,226,000 after buying an additional 519,650 shares in the last quarter. Finally, TimesSquare Capital Management LLC purchased a new stake in Sarepta Therapeutics in the third quarter worth about $21,521,000. 82.41% of the stock is currently owned by hedge funds and other institutional investors.
In related news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the business’s stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $55.89, for a total transaction of $372,618.63. Following the transaction, the director now directly owns 13,333 shares in the company, valued at approximately $745,181.37. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 9.60% of the company’s stock.
Shares of Sarepta Therapeutics Inc (SRPT) traded up $0.31 during trading hours on Wednesday, hitting $58.87. The stock had a trading volume of 757,300 shares, compared to its average volume of 1,764,972. Sarepta Therapeutics Inc has a twelve month low of $26.96 and a twelve month high of $68.90. The stock has a market cap of $3,850.00, a P/E ratio of -29.19 and a beta of 1.49. The company has a debt-to-equity ratio of 0.04, a current ratio of 10.44 and a quick ratio of 9.52.
Several research firms recently issued reports on SRPT. BidaskClub cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday. HC Wainwright set a $75.00 target price on Sarepta Therapeutics and gave the stock a “buy” rating in a research report on Monday. William Blair reiterated an “outperform” rating on shares of Sarepta Therapeutics in a research report on Monday, February 5th. Zacks Investment Research raised Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, February 7th. Finally, Barclays reissued a “hold” rating and set a $55.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, January 23rd. One analyst has rated the stock with a sell rating, six have given a hold rating and seventeen have issued a buy rating to the stock. Sarepta Therapeutics has an average rating of “Buy” and a consensus target price of $64.65.
WARNING: “Sarepta Therapeutics Inc (NASDAQ:SRPT) Position Boosted by Hall Laurie J Trustee” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/14/sarepta-therapeutics-inc-srpt-shares-bought-by-hall-laurie-j-trustee.html.
Sarepta Therapeutics Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.